Determination of the PSMA affinity was performed by saturation binding assays using PC-3 PIP cells and different concentrations of nat/44Sc-, nat/177Lu-, nat/68Ga-PSMA-617, or nat/68Ga-PSMA-11, respectively (Additional file 1). The relative affinities were defined as the average of at le...
Palliative targeted radionuclide therapy with Lutetium-177 labelled PSMA-617 (177Lu-PSMA) is increasingly used in metastatic castration-resistant prostate cancer and well-tolerated with few side effects [14, 15]. Because of the clear visualization of AdCC and possible other salivary gland cancer local...
177Lu-PSMA-617治疗转移性前列腺癌的安全性和疗效 摘要 著录项 南京医科大学附属南京医院、南京市第一医院核医学科 210006; 南京医科大学附属南京医院、南京市第一医院核医学科 210006; 南京医科大学附属南京医院、南京市第一医院核医学科 210006; 南京医科大学附属南京医院、南京市第一医院核...
4022541Ac-PSMA-617_4017741Lu-PSMA-617tandemtherapyofmetastaticcastration-resistantprostatecancer_pilotexperience462020Eur 系统标签: psmaprostatecastrationtherapytandemmetastatic ORIGINALARTICLE225Ac-PSMA-617/177Lu-PSMA-617tandemtherapyofmetastaticcastration-resistantprostatecancer:pilotexperienceFadiKhreish1&NiklasEbert...
177治疗性放射性药物作为前列腺特异性膜抗原抑制剂(iPSMA),其中与杂环肼基烟酰胺(HYNIC)结合的1,4,7,10‑四氮杂环十二烷‑N,N,N”,N””‑四乙酸(DOTA)生成使构象异构体和分子内氢键的数量最小化的刚性化学结构,从而产生分子中的活性位点(Lys(Nal)‑NH‑CO‑NH‑Glu)对于PSMA蛋白的生物识别有...
Four patients prematurely discontinued therapy: three due to disease progression and one due to demotivating (grade 1) side-effects. Conclusions Palliative 177 Lu-PSMA therapy for salivary gland cancer may lead to rapid relief of tumour-associated discomfort and may even induce disease stabilization. ...
摘要: Purpose Dosimetry is critical to achieve the optimal therapeutic effect of radioligand therapy (RLT) with limited side effects. Our aim was to perform image-based absorbed dose calculation for the new... 展开 关键词: Prostate cancer PSMA mCRPC Lutetium-177 Dosimetry Radioligand radiation the...
177Lu-FAP-2286全身和骨髓吸收剂量(分别为0.07和0.05 Gy/GBq)与177Lu-PSMA-617(分别为0.04和0.03 Gy/GBq)和177Lu-DOTATATE(分别为0.05和0.04 Gy/GBq)相似。骨转移的吸收剂量与Kulkarni等人报告的177Lu-PSMA-617相似[177Lu-FAP-2286...
(lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has...
EAST HANOVER, N.J., March 23, 2022 -- Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) for the treatment of adult patients with a certain type of advanced cancer...